Clinical Trials · NCT00056654
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Abbott
- Enrollment
- 164
- Start date
- Mar 2003
- Locations
- 55 sites, United States
- Primary endpoint
- Suppression of serum testosterone (<=50 ng/dL) and maintenance of serum testosterone suppression once suppression is achieved for individual subjects.